Suraksha Diagnostic Ltd. (IN:SURAKSHA)
:SURAKSHA
Want to see IN:SURAKSHA full AI Analyst Report?
SURAKSHA Stock Chart & Stats
₹300.85
-₹13.40(-3.48%)
At close: 4:00 PM EST
₹300.85
-₹13.40(-3.48%)
Day’s Range― - ―
52-Week Range₹224.10 - ₹353.65
Previous CloseN/A
Volume140.52K
Average Volume (3M)1.23K
Market Cap
₹14.76B
Enterprise Value₹15.78B
Total Cash (Recent Filing)₹435.94M
Total Debt (Recent Filing)₹1.18B
Price to Earnings (P/E)46.7
Beta1.21
Next Earnings
Jun 03, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)1.60
Shares Outstanding52,080,757
10 Day Avg. Volume1,073
30 Day Avg. Volume1,225
Financial Highlights & Ratios
PEG Ratio1.29
Price to Book (P/B)6.74
Price to Sales (P/S)5.65
P/FCF Ratio66.71
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)7.15
Revenue Forecast (FY)₹3.49B
Bulls Say, Bears Say
Bulls Say
High Profitability MarginsSustained high gross and healthy net margins indicate durable pricing power and efficient laboratory operations. Such margins support reinvestment in capacity and technology, provide a cushion against reimbursement pressure, and improve long-term free cash flow potential.
Consistent Revenue GrowthDouble-digit revenue growth reflects sustained demand and successful scale-up of testing volumes or geographic expansion. Continued top-line growth supports fixed-cost leverage, margin sustainability, and justifies incremental capex to expand network reach over the medium term.
Strong Cash GenerationRobust operating cash conversion and substantial FCF growth demonstrate effective working-capital and capex management. Reliable cash generation enables internal funding for expansion, debt servicing or strategic investments without immediate reliance on external financing.
Bears Say
Rising Liabilities TrendA gradual rise in total liabilities, despite moderate leverage today, raises medium-term risk if growth requires additional funding or if interest costs increase. Persistent liability growth could limit flexibility for capex or acquisitions and elevate refinancing risk.
Moderate FCF Conversion RatioA 0.67 FCF-to-net-income ratio means a notable portion of accounting profits isn't translating to free cash. Over time this can constrain the company’s ability to self-fund larger expansion, increase dividends, or accelerate debt reduction without improving working-capital efficiency.
No Dividend YieldNot paying dividends limits direct shareholder returns and may reduce appeal to income-focused investors. If growth moderates, absence of a return-of-capital policy could pressure investor support; returning cash could validate the company’s strong cash-generation claims.
Suraksha Diagnostic Ltd. News
SURAKSHA FAQ
What was Suraksha Diagnostic Ltd.’s price range in the past 12 months?
Suraksha Diagnostic Ltd. lowest stock price was ₹224.10 and its highest was ₹353.65 in the past 12 months.
What is Suraksha Diagnostic Ltd.’s market cap?
Suraksha Diagnostic Ltd.’s market cap is ₹14.76B.
When is Suraksha Diagnostic Ltd.’s upcoming earnings report date?
Suraksha Diagnostic Ltd.’s upcoming earnings report date is Jun 03, 2026 which is in 33 days.
How were Suraksha Diagnostic Ltd.’s earnings last quarter?
Suraksha Diagnostic Ltd. released its earnings results on Feb 05, 2026. The company reported ₹1.6 earnings per share for the quarter, beating the consensus estimate of N/A by ₹1.6.
Is Suraksha Diagnostic Ltd. overvalued?
According to Wall Street analysts Suraksha Diagnostic Ltd.’s price is currently Overvalued.
Does Suraksha Diagnostic Ltd. pay dividends?
Suraksha Diagnostic Ltd. does not currently pay dividends.
What is Suraksha Diagnostic Ltd.’s EPS estimate?
Suraksha Diagnostic Ltd.’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Suraksha Diagnostic Ltd. have?
Suraksha Diagnostic Ltd. has 52,080,757 shares outstanding.
What happened to Suraksha Diagnostic Ltd.’s price movement after its last earnings report?
Suraksha Diagnostic Ltd. reported an EPS of ₹1.6 in its last earnings report, beating expectations of N/A. Following the earnings report the stock price went up 0.228%.
Which hedge fund is a major shareholder of Suraksha Diagnostic Ltd.?
Currently, no hedge funds are holding shares in IN:SURAKSHA
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Suraksha Diagnostic Ltd.
Established in 1992 as Suraksha Diagnostics & Eye Centre (P) Ltd. in Kolkata, they started as one of the first diagnostic centers in Kolkata to provide all pathology and radiology services under one roof. This convenience, along with their unwavering commitment to accuracy and service, resulted in steady growth and popularity. Within 3 years they could confidently open a second Center at Siliguri, in North Bengal, which remains the largest such facility in the region, and today serves not only to patients from North Bengal, but also neighbouring States and countries. Since then they have grown steadily across Bengal, Bihar, and Delhi NCR.
Technical Analysis
Indraprastha Medical Corporation Limited
―
Krsnaa Diagnostics Limited
―
Dr. Lal PathLabs Limited
―
Metropolis Healthcare Ltd.
―
Vijaya Diagnostic Centre Ltd.
―